Tengion snags a $15M lifeline in last-ditch drive to survive

By John Carroll After burning through close to $239 million over a decade the struggling regenerative medicine company Tengion has rounded up $15 million from investors in what ...

India’s Advinus inks $36M drug discovery pact with Takeda

By John Carroll India’s biotech industry is better known for its contract research operations than novel drug development. But Advinus Pharma, a biotech company supported by ...

Momenta Pharma options antibody against red meat-related inflammation

By Ryan McBride Another West Coast biotech startup has set sail for the Boston area. Sialix, a spinoff from the University of California, San Diego, has staked out office space in ...

Merger deal gives generic drugmaker control of troubled BioSante

By John Carroll The generic drugmaker ANI Pharmaceuticals has stepped up to take over troubled BioSante as the biotech preps for Round Two of its failed late-stage program for a female ...

Promising prostate cancer data triggers $50M venture haul for Aragon

By John Carroll Just days after reporting positive interim results from a mid-stage study of its closely-watched prostate cancer drug, San Diego-based Aragon Pharmaceuticals has ...

Report: Biosimilars team at Teva/Lonza slams the brakes on Rituxan knockoff

By John Carroll Three years after Teva and Switzerland’s Lonza joined forces to create a new joint venture to develop a few blockbuster biosimilars, one of their lead programs ...

Mylan sues FDA to revoke Ranbaxy’s Diovan exclusivity

Two weeks after Novartis’ patent expired, Ranbaxy hasn’t launched a generic By Tracy Staton Mylan ($MYL) has sued FDA for the right to sell a version of Novartis’ ...

Teva yanks Wellbutrin copy after FDA says it’s not equivalent to brand

By Tracy Staton Generics giant Teva Pharmaceutical Industries ($TEVA) is pulling its version of Wellbutrin XL. No, it’s not a quality-control-related recall. It’s something ...

India nixes Pfizer’s patent on cancer-fighter Sutent

IP move is the latest to undermine Big Pharma’s standing in the country By Tracy Staton India has blown another raspberry at Big Pharma. In its third strike against foreign drugmakers, ...

J&J aims to block ex-FDA chief’s testimony in Risperdal case

By Tracy Staton Lawyers are pulling no punches in that Risperdal litigation playing out in Philadelphia court. After trying to force Johnson & Johnson CEO Alex Gorsky onto ...

Drug billionaire to match cancer with treatment via blazing-fast DNA analysis

By Tracy Staton The richest man in Los Angeles got that way by building drug companies. Now, he wants to build a nation-wide system that allows doctors to decode their patients’ ...

NVO’s Tresiba Approved in Japan

By Zacks Equity Research Denmark based Novo Nordisk (NVO) recently announced that its candidate Tresiba (insulin degludec) has received approval in Japan. The Japanese Ministry of ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS